Medical Animation Lupus

Live Web Chat Examines Healthy Eating And Weight Management In Lupus
An estimated 1.5 million Americans and at least five million people worldwide are living with some form of lupus, an unpredictable and potentially fatal autoimmune disease. While medications are important to managing lupus, there also are a number of lifestyle adjustments people with lupus can make to help keep the physical symptoms of the disease under control. Diet and weight management are important tools.

Women With Lupus At Risk For Heart Disease
Women with the autoimmune disease systemic lupus erythematosus (SLE) have a more than two-fold increased risk of cardiovascular disease over women without the disease according to research funded in part by the Arthritis Foundation. The research was presented this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco.

Nicole Paxson Helps Women With Lupus Feel Beautiful And Confident - The Lupus Foundation
Teen girls are often naturally self-conscious about their looks. Imagine being a 12-year-old girl out on a school field trip and suddenly having welts and rashes appear on your arms. This is how Nicole Paxson eventually learned that she had lupus, an unpredictable and potentially life-threatening autoimmune disease that affects mostly young women.

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity In Patients With Lupus
UCB (Euronext Brussels: UCB) announced data from two randomized controlled trials showing that treatment with epratuzumab a humanized anti-CD22 antibody, resulted in clinically meaningful reduced disease activity, improved health-related quality of life (HRQoL) measurements and reduced reliance on corticosteroids compared to placebo treatment in patients with active moderate and severe systemic lupus erythematosus (SLE).

How Women With Lupus Can Increase Chance For Healthy Pregnancies
In the not so distant past, women with systemic lupus erythematosus (SLE), an autoimmune disease, were advised not to have children, and if they became pregnant, to have therapeutic abortions to prevent severe flares of their lupus. Research by rheumatologists at Hospital for Special Surgery in New York, in patients with lupus who have had successful pregnancies is yielding insights that support a reversal of that thinking.

Lupus Foundation Of America Awards More Than $1.1 Million In New Research Grants
The Lupus Foundation of America (LFA) has awarded more than $1.1 million in new research grants and fellowships as part of its ongoing commitment to bringing down the barriers in developing new treatments and finding a cure for lupus. Lupus is a disabling and life-threatening autoimmune disease that affects approximately 1.5 million Americans -- that's enough people to fill 30 baseball stadiums.

Dr. Betty Diamond To Receive Prestigious Evelyn V. Hess Award Recognizing A Lifetime Of Achievement In Lupus Research
Betty Diamond, M.D., Head of the Autoimmune Disease Center at The Feinstein Institute for Medical Research, and Professor of Medicine at the Albert Einstein College of Medicine, is the 2008 recipient of the prestigious Evelyn V. Hess Research Award, given annually by the Lupus Foundation of America, Inc. (LFA). The recipient is selected through a peer review process, and recognizes a lifetime of achievement in lupus research. Dr.

Lupus Foundation Of America's Live Webchat To Discuss Reproductive Health And Lupus
Because 90 percent of the estimated 1.5 million Americans living with the autoimmune disease lupus are female, fertility, pregnancy and reproductive health are important issues of concern. Women with lupus no longer are told not to have children. However, they are advised to take steps to plan before conception so physicians can monitor these high-risk pregnancies at every step.

The Merinoff Symposia To Highlight New Research In Systemic Lupus
The Feinstein Institute for Medical Research is hosting a three-day meeting for scientists interested in learning about the latest scientific studies underway in understanding and treating Systemic Lupus. Feinstein scientists are known worldwide for their contributions to the field of immunology, and in particular lupus and other autoimmune diseases, and have organized a novel meeting to share the science with immunologists on the front lines of taking care of patients.

Human Genome Sciences Completes Enrollment In Second Phase 3 Lymphostat-B(R) Trial
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B® (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006.

LFA Launches Center For Clinical Trials Education
The Lupus Foundation of America (LFA) has announced the launch of the Center for Clinical Trials Education (CCTE), a resource for people interested in learning about and joining lupus clinical trials. The initial programs of the CCTE include a Website (www.lupus.

Lupus Foundation Of America Launches Center For Clinical Trials Education
The Lupus Foundation of America (LFA) has announced the launch of the Center for Clinical Trials Education (CCTE), a resource for people interested in learning about and joining lupus clinical trials. The initial programs of the CCTE include a Website and a series of grassroots community education programs on clinical research offered through the LFA's network of 38 chapters around the country.

Karen Evans Elected Chair Of Lupus Foundation Of America, Inc. National Board Of Directors
Karen Evans of Baltimore, Maryland was elected Chair of the Lupus Foundation of America, Inc. (LFA) Board of Directors during the Foundation's recent Annual Meeting in San Antonio, Texas. Ms. Evans will lead the LFA Board's strategic initiatives to bring national attention and increased public and private resources to fight lupus, an unpredictable and potentially fatal autoimmune disease. Ms.

MedImmune Initiates First Phase 2 Trial In Lupus Patients With Its Antibody Targeting Interferon-alpha
MedImmune announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with systemic lupus erythematosus (SLE or lupus). The study is designed to assess the safety and tolerability of the antibody, also known as MEDI-545 in patients with moderately to severely active lupus, despite standard of care.

Medarex Announces Initiation Of Phase 2 Clinical Development Program For The Treatment Of Lupus
Medarex, Inc. (Nasdaq: MEDX) announced that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount.